What investment strategy does GHO Capital focus on?

GHO Capital focuses on Buyout, Growth strategies in the private equity space.

How many portfolio companies does GHO Capital have?

GHO Capital has 13 active portfolio companies and 7 completed exits and 4 funds tracked on GP Intel.

Where is GHO Capital headquartered?

GHO Capital is headquartered in London, United Kingdom.

What is GHO Capital's assets under management?

GHO Capital manages approximately €9.0B in assets under management.

When was GHO Capital founded?

GHO Capital was founded in 2014.

What sectors does GHO Capital invest in?

GHO Capital invests across Healthcare, Industrials.

Home/GPs/GHO Capital

GHO Capital

London, United Kingdom·Founded 2014·

Buyout Growth Equity

·ghocapital.com

GHO Capital (Global Healthcare Opportunities) is a London-based specialist healthcare investment firm founded in 2014, regulated by the FCA under firm reference number 1044842. It invests in companies with a European presence and global potential across outsourced pharma services, PharmaBio, MedTech and patient services, deploying capital through discrete buyout and growth funds. The firm closed Fund IV at over EUR 2.5bn in 2025, bringing assets under management to around EUR 9bn and making it the largest healthcare specialist private equity firm headquartered in Europe.

AUM

€9.0B

Funds

vintages 2015–2025

Portfolio

Exits

SectorsHealthcareIndustrials

Key facts

HQLondon, United Kingdom

Founded2014

Employees66+

Websiteghocapital.com

Recent exits

Biocare Medical

MedTech · 2026 · 5yr hold

VISUfarma

Pharma · 2026 · 10yr hold

FairJourney Biologics

Biotech · 2024 · 4yr hold

BioAgilytix

Biotech · 2021 · 3yr hold

Coverage notes

4 funds tracked, 20 portfolio companies (13 active · 7 realized). Verified weekly from public filings and deal announcements.

Funds & portfolio

Every fund GHO Capital has raised, with its portfolio companies. Hand-checked from public filings.

4 funds

GHO Capital IV LPBuyout

2025 · 1yr€2.5B3 active

Unrealized

3 held

Company	Sector	Geo	Entry
Avid Bioservices	Biotech	United States	2025
FotoFinder Systems	MedTech	Germany	2025
Scientist.com	HealthTech	United States	2025

Avid BioservicesActive

BiotechUnited States· Entry 2025

FotoFinder SystemsActive

MedTechGermany· Entry 2025

Scientist.comActive

HealthTechUnited States· Entry 2025

GHO Capital III LPBuyout

2021 · 5yr€2.0B7 active · 1 realized

Unrealized

7 held

Company	Sector	Geo	Entry
Alcami Corporation	Pharma	United States	2022
Clearview Healthcare Partners	Business Services	United States	2021
Genesis Research	HealthTech	United States	2021
Roslinct	Biotech	UK	2021
Sanner	MedTech	Germany	2022
Sapio Sciences	HealthTech	United States	2022
Velocity Clinical Research	HealthTech	United States	2021

Alcami CorporationActive

PharmaUnited States· Entry 2022

Clearview Healthcare PartnersActive

Business ServicesUnited States· Entry 2021

Genesis ResearchActive

HealthTechUnited States· Entry 2021

RoslinctActive

BiotechUK· Entry 2021

SannerActive

MedTechGermany· Entry 2022

Sapio SciencesActive

HealthTechUnited States· Entry 2022

Velocity Clinical ResearchActive

HealthTechUnited States· Entry 2021

Realized

1 exit

Company	Sector	Geo	Entry	Exit	Type	Buyer	MOIC
Biocare Medical	MedTech	United States	2021	2026	Trade Sale		–

Biocare MedicalExited 2026

MedTechUnited States· Entry 2021

Trade Saleto

GHO Capital Fund II LPBuyout

2019 · 7yr€975M3 active · 1 realized

Unrealized

3 held

Company	Sector	Geo	Entry
Ardena	Pharma	Belgium	2020
Sterling Pharma Solutions	Pharma	UK	2019
Validant	Business Services	United States	2022

ArdenaActive

PharmaBelgium· Entry 2020

Sterling Pharma SolutionsActive

PharmaUK· Entry 2019

ValidantActive

Business ServicesUnited States· Entry 2022

Realized

1 exit

Company	Sector	Geo	Entry	Exit	Type	Buyer	MOIC
FairJourney Biologics	Biotech	Portugal	2020	2024	Secondary		–

FairJourney BiologicsExited 2024

BiotechPortugal· Entry 2020

Secondaryto

GHO Capital Fund I LPBuyout

2015 · 11yr€660M0 active · 5 realized

Realized

5 exits

Company	Sector	Geo	Entry	Exit	Type	MOIC
BioAgilytix	Biotech	United States	2018	2021	Trade Sale	–
Caprion Biosciences	Biotech	Canada	2016	2019	Secondary	–
DNA Diagnostics Center	Healthcare	United States	2015	2021	Trade Sale	–
Quotient Sciences	Pharma	UK	2015	2019	Secondary	–
VISUfarma	Pharma	UK	2016	2026	Trade Sale	–

BioAgilytixExited 2021

BiotechUnited States· Entry 2018

Trade Saleto

Caprion BiosciencesExited 2019

BiotechCanada· Entry 2016

Secondaryto

DNA Diagnostics CenterExited 2021

HealthcareUnited States· Entry 2015

Trade Saleto

Quotient SciencesExited 2019

PharmaUK· Entry 2015

Secondaryto

VISUfarmaExited 2026

PharmaUK· Entry 2016

Trade Saleto

Track GHO Capital

Saved GPs appear in your watchlist, one click from your workspace.

About GHO Capital

GHO Capital is an alternative investment platform with capital deployed across 4 active fund vehicles, headquartered in London. The firm deploys capital across European mid and small-cap businesses spanning healthcare and industrials.

Investment thesis

The platform combines complementary investment strategies, deploying capital across healthcare and industrials businesses in the United Kingdom and broader European market. Multi-strategy capital deployment enables flexibility across the business lifecycle, with the partnership culture supporting management teams through growth, transmission and selective M&A across multiple fund vintages and asset classes.

Recent activity

Realised exits across the current platform vintages remain limited, with the portfolio in active deployment and value-creation phase. The platform tracks 4 fund vehicles, 14 active portfolio companies and 0 realised exits across the strategy's history. Detailed buyer names and multiple data available on Pro at €29/month.